Labcorp to Buy Myriad's Prenatal Testing Unit in Definitive Deal
LH sits 26% above its 52-week low of $244.52.
Summary
Labcorp signed a definitive agreement to acquire Myriad Genetics' prenatal health testing business for $210M in cash, plus the value of the prenatal health testing business's inventory at closing, adding another bolt-on to a busy 2026 M&A run that already includes MLM Medical Labs and up to $872M for select BioReference assets from OPKO. Labcorp expects the transaction to add about $160M in revenue in year one, to be slightly accretive to adjusted earnings in year one, and to reach average diagnostics segment margins by the end of year two once fully integrated. For Myriad, the sale offloads a non-core unit and sharpens focus on its core molecular diagnostics; for Labcorp, it deepens women's health and reproductive testing within its diagnostics segment. The strategic fit is consistent with Labcorp's stated 5-8% revenue CAGR target through 2029. Watch for the 8-K with closing conditions, plus any antitrust review timeline.
At the time of this announcement, LH was trading at $307.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.9B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.